Evidence map›Paper›PMID 42777143›Full record

ArticleCancer research communications2026

Breast Cancer-Protective Genetic Variant Common in Women of Indigenous American Genetic Ancestry Is a cis-eQTL for RMND1, ARMT1, and CCDC170 in HER2-Enriched Tumor Subtypes.

Valentina A Zavala, Xiaosong Huang, Sandro Casavilca-Zambrano, Jeannie Navarro-Vásquez, Carlos A Castañeda, Guillermo Valencia, Zaida Morante, Monica Calderón, Julio E Abugattas, Henry Gómez and 18 more

Abstract read
In one paragraph

Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Valentina A ZavalaDepartment of Public Health Sciences, University of California, Davis, Davis, California.ORCID 0000-0003-2040-1760
Xiaosong HuangDepartment of Public Health Sciences, University of California, Davis, Davis, California.ORCID 0000-0003-0627-1509
Sandro Casavilca-ZambranoInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0001-8406-739X
Jeannie Navarro-VásquezInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0009-0000-0775-8832
Carlos A CastañedaInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0001-6200-0856
Guillermo ValenciaInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0002-4234-4448
Zaida MoranteInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0003-2952-6068
Monica CalderónInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0003-4935-7927
Julio E AbugattasInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0002-9806-0989
Henry GómezInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0003-2660-1843
Hugo A FuentesInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0002-2747-7381
Ruddy Liendo-PicoagaInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0003-3570-8802
Jose M CotrinaInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0002-8330-803X
Claudia Monge-PimentelInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0002-1215-5857
Silvia P NeciosupInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0002-2657-9853
Jule VásquezInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0001-6477-4660
Marco Gálvez-NiñoInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0002-1408-4474
Víctor CastroInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0003-2828-7325
Luis A Salinas AgramonteInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0009-0006-2560-3934
Patricia Rioja VieraInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0003-3141-7418
Mileine Bravo-PoemapeInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0009-0003-0711-9813
Luis MasInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0002-2323-9271
Scott HuntsmanDivision of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-5440-6191
Donglei HuDivision of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-0351-001X
Jovanny ZabaletaDepartment of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana.ORCID 0000-0002-5961-6761
Elad ZivDivision of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2324-2884
Tatiana VidaurreInstituto Nacional de Enfermedades Neoplasicas , Lima, Peru.ORCID 0000-0003-1995-4560
Laura FejermanDepartment of Public Health Sciences, University of California, Davis, Davis, California.ORCID 0000-0003-3179-1151

Funding

Latin America Genomics of Breast Cancer Risk Study (LAGENO-BCR)R01CA286650 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Julie Dutil, Laura Fejerman · 2024 to 2026
$2.5M
Biological implications of breast cancer protective variants in Latin Americanwomen with high Indigenous American ancestryR01CA204797 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FEJERMAN, LAURA · 2016 to 2020
$1.9M
Her2 status of breast cancer in diverse populations: improving genetic prediction and understanding molecular correlatesR01CA273313 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Laura Fejerman · 2023 to 2026
$1.8M
American Association for Cancer Research (AACR) 21-40-18-ZAVANational Cancer Institute (NCI) R01CA204797National Cancer Institute (NCI) R01CA273313National Cancer Institute (NCI) R01CA286650NCI NIH HHS R01 CA204797NCI NIH HHS R01 CA273313NCI NIH HHS R01 CA286650
6 · The paper itself

Abstract

Breast cancer genome-wide association studies in Hispanic/Latina women in the United States and Latin America have identified independent risk variants in the 6q25 region, including the protective variant rs140068132, located upstream of the estrogen receptor 1 (ESR1) gene. The molecular mechanisms linking this and other variants to breast cancer risk remain poorly understood. To investigate the potential functional role of rs140068132, we analyzed the association between this variant and gene expression in breast cancer tissue. We performed RNA sequencing on 270 tumors from the Peruvian Genomics of Breast Cancer Study and determined intrinsic tumor subtypes using PAM50. The effect of rs140068132 on gene expression across tumor subtypes was assessed using models adjusted for age at diagnosis, Indigenous American genetic ancestry, PAM50 subtype, and an interaction term between tumor subtype and SNP genotype. Subtype-specific effects of the protective rs140068132-G allele were observed in HER2-enriched tumors, with increased expression of ARMT1, RMND1, and CCDC170. These results suggest that in breast cancer tissue from Peruvian patients, rs140068132 influences the expression of multiple genes in a subtype-specific manner, likely acting through a regulatory element at 6q25 that modulates gene expression in cis depending on cellular context. SIGNIFICANCE: A protective germline variant, common in women of Indigenous American ancestry, upregulates the expression of cis-genes only in HER2-enriched tumors, providing valuable information for model selection in downstream mechanistic studies.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMiddle AgedPeruPolymorphism, Single NucleotideERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID42777143
PMCPMC13651766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.